---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-095633"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2022-04-05T23:59:59+00:00"
generated_at: "2026-06-26T09:31:55.099451+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Gemini Therapeutics CMO Samuel Barone to depart April 15, 2022; advisory role continues

## Summary
- Dr. Samuel Barone will leave as Chief Medical Officer effective April 15, 2022.
- He receives 9 months base salary severance, pro-rata 2022 target bonus, and 9 months COBRA.
- Barone will stay on as advisor, continuing to vest in existing equity during the advisory period.
- Retention Agreement terms from Oct 4, 2021 govern severance; general release required.

## SEC filing metadata
- accession: 0001193125-22-095633
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2022-04-05T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312522095633/0001193125-22-095633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312522095633/d345871d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-095633
- JSON: https://secwatch.observer/filing/0001193125-22-095633.json
- Plain text: https://secwatch.observer/filing/0001193125-22-095633.txt

## Key facts
- Executive change
  Samuel Barone departed as Chief Medical Officer at Disc Medicine, Inc..
  - Action: depart
  - Role: Chief Medical Officer
  source text: Effective as of April 15, 2022 (the “Separation Date”), Samuel Barone, M.D. will depart as the Chief Medical Officer of Gemini Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312522095633/0001193125-22-095633-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.